Zentalis Pharmaceuticals, Inc. $ZNTL Shares Sold by Tybourne Capital Management HK Ltd.

Tybourne Capital Management HK Ltd. decreased its stake in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 35.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 961,486 shares of the company’s stock after selling 516,666 shares during the period. Zentalis Pharmaceuticals makes up 4.7% of Tybourne Capital Management HK Ltd.’s portfolio, making the stock its 4th biggest position. Tybourne Capital Management HK Ltd. owned about 1.33% of Zentalis Pharmaceuticals worth $1,452,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently made changes to their positions in the stock. AQR Capital Management LLC increased its stake in shares of Zentalis Pharmaceuticals by 177.6% during the first quarter. AQR Capital Management LLC now owns 619,330 shares of the company’s stock valued at $985,000 after acquiring an additional 396,233 shares during the period. Millennium Management LLC boosted its stake in Zentalis Pharmaceuticals by 220.6% during the 1st quarter. Millennium Management LLC now owns 3,069,514 shares of the company’s stock valued at $4,881,000 after purchasing an additional 2,111,951 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new position in Zentalis Pharmaceuticals during the 2nd quarter valued at $38,000. Savant Capital LLC acquired a new position in shares of Zentalis Pharmaceuticals during the 2nd quarter valued at $59,000. Finally, Acadian Asset Management LLC raised its stake in shares of Zentalis Pharmaceuticals by 4.7% in the 2nd quarter. Acadian Asset Management LLC now owns 2,799,020 shares of the company’s stock worth $3,241,000 after buying an additional 124,985 shares in the last quarter.

Insider Activity at Zentalis Pharmaceuticals

In related news, major shareholder Matrix Capital Management Comp sold 7,500,000 shares of the firm’s stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $1.33, for a total value of $9,975,000.00. Following the completion of the transaction, the insider owned 6,459,973 shares of the company’s stock, valued at approximately $8,591,764.09. This trade represents a 53.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Group Walters bought 6,459,973 shares of Zentalis Pharmaceuticals stock in a transaction dated Wednesday, December 31st. The stock was acquired at an average price of $1.20 per share, with a total value of $7,751,967.60. Following the acquisition, the insider directly owned 13,509,973 shares of the company’s stock, valued at approximately $16,211,967.60. This represents a 91.63% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders sold 7,503,096 shares of company stock valued at $9,982,878. 1.90% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on ZNTL. Wedbush reaffirmed a “neutral” rating and set a $4.00 target price on shares of Zentalis Pharmaceuticals in a research note on Tuesday, November 11th. Leerink Partners reissued a “market perform” rating and issued a $2.00 price target on shares of Zentalis Pharmaceuticals in a report on Tuesday, November 11th. Morgan Stanley lowered their price objective on shares of Zentalis Pharmaceuticals from $8.00 to $4.00 and set an “equal weight” rating on the stock in a research note on Wednesday, November 12th. Finally, Wall Street Zen raised shares of Zentalis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, November 16th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $5.00.

Zentalis Pharmaceuticals Trading Up 0.4%

Shares of ZNTL opened at $2.40 on Tuesday. The business’s 50-day moving average price is $2.10 and its 200 day moving average price is $1.73. The stock has a market capitalization of $173.40 million, a P/E ratio of -1.16 and a beta of 1.72. Zentalis Pharmaceuticals, Inc. has a 1-year low of $1.01 and a 1-year high of $3.95.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings data on Monday, November 10th. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.12. On average, research analysts predict that Zentalis Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.